Radioiodine-Resistant Differentiated Thyroid Cancer: Hope for the Future
The authors highlight promising novel molecular agents—including sorafenib and sunitinib—that offer therapeutic options for patients with radioiodine‑resistant differentiated thyroid cancer, and call for systematic large‑scale clinical trials to establish efficacy and safety.
This review informs clinicians about emerging targeted therapies for a subset of thyroid cancer patients who no longer respond to standard radioiodine treatment, potentially improving outcomes and guiding future trial designs.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management